Recent evaluation of anticoagulant effects, which include antiaggregants and fibrinolytics, is based on monitoring of hemostatic properties, according to the results of clotting, amidolytic, and immunferment methods. Despite the lack of sensitivity, complexity of standardization, long duration of sample preparation, and usage of citric plasma model, the evaluation of anticoagulant effects meets increasing growth in demand by clinical practice and expertise. However, in the evaluation of hemostasis and its reaction to conducting a therapy, the exclusion of the effects of formed elements of blood and endothelial cells (evaluation in plasma + long duration of sample preparation) leads to undercounting of the nuances of consistency of hemostatic potential (HP) (integrative element of complete cycle of hemocoagulation that provides necessary fluidity of blood and restriction of extravasation of its components in breakage or damage of vascular wall).
Enzyme potential of endothelial intravascular continuum determines temporary determinant of nonlinearity of fibrogenesis. Without disputing the positional postulate of the primacy of thrombin in this process, it is essential to understand that its amount (level) or, most likely, its activity determines the completeness or incompleteness of fibrogenesis in conditions of limiting the rate of its formation by metabolic products of fibrinogen and producers of the vascular wall. Therefore, seconds and even milliseconds, required for the generation of thrombin, are sufficient for initiation of fibrogenesis, while its consistency is directly related to the intensity and magnitude of thrombin formation pool. Maxim Solovyev, Innovation technology evaluation of effectivness of antiagregates, anticoagulants, and fibrinolytics
Last date updated on June, 2014